| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_ITCH_0031200 | Exon-Exon | chr20:33096322-33096541 | chr20:34508517-34508736 | 220 nt | 0.4455 |
| hsa_chr20_0093700 | Intergenic-Intergenic | chr20:33097761-33098103 | chr20:34509956-34510298 | 343 nt | 0.3469 |
| hsa_ITCH_0031300 | Exon-Exon | chr20:33098387-33098564 | chr20:34510582-34510759 | 178 nt | 0.3652 |
| hsa_FDX1P1_0000100 | Intergenic-Exon-Intergenic | chr20:33049994-33068959 | chr20:34462189-34481154 | 650 nt | 0.3969 |
| hsa_FDX1P1_0000200 | Exon-Intergenic | chr20:33063970-33064360 | chr20:34476165-34476555 | 391 nt | 0.5857 |
A review consolidating research in humans and model organisms indicates that the circITCH functions as a tumor suppressor in glioma by sponging miR-214 to allow expression of ubiquitin-protein ligase E3, thereby suppressing proliferation and preventing apoptosis, while also targeting the Wnt/β-catenin pathway [Mehta et al. DOI:10.1016/j.pneurobio.2020.101746]. In oesophageal squamous cell carcinoma, the circITCH is downregulated and increases ITCH expression to inhibit the Wnt/β-catenin pathway [Lee et al. DOI:10.1016/j.biopha.2018.12.052]. circITCH hsa_circ_0001141 (circITCH) was found to be lower in the hearts of cancer patients suffering from doxorubicin-induced cardiomyopathy compared to those with dilated cardiomyopathy, hypertrophic cardiomyopathy, and healthy donors, and its expression ameliorates doxorubicin-induced cardiomyocyte injury [Tian et al. DOI:10.3390/molecules26041155].